Who do I have to suck for some eloralintide

I seen the reta phase 3 study was posted on Meso. Not intelligent enough to copy and paste... couldnt share or copy for whatever reason.
If they're posting studies on Meso about whether attitude counts more than previous experience in that arena, then I'm gonna take back a LOT of the dismissive things I've implied about the Meso crowd before.
 
From what I am reading Eloralintide is difficult to produce. It requires specialized equipment and has lower yields. Maybe the CN producers will decide it is just not cost effective.

I still want to try it, but I'm not going to pay substantially higher prices for it.
 
From what I am reading Eloralintide is difficult to produce. It requires specialized equipment and has lower yields. Maybe the CN producers will decide it is just not cost effective.

I still want to try it, but I'm not going to pay substantially higher prices for it.
Where are you reading that? I would like more info about it.
 
Last edited:
NFN this thread was started back in Nov.
This reminds me of that Unicornutide, I had ordered. 🤣
 
Found a producer and got quoted: 1 gram Eloralintide raw powder: USD 5'500 ... minimum order - I think I might get a Rolex instead ;-) and look at the time flying by until it gets more affodable. ... and raw powder is less stable - meaning lasts not as long... ;-)
 
Last edited:
I got quoted 1 Gram for $1500. Which actually is not horrible. Obviously would need to find someone to lyophilize the API into powder and vials, but hey 100mg for $150 seems to be more reasonable.

Though with it being such a new compound there are many unknowns and perhaps there are more barriers to producing then us laymen think. Would also need an HPLC test to verify the purity. Wish this compound was getting as much hype as Reta.

https://www.prnewswire.com/news-rel...efficacy-in-preclinical-models-302715843.html

This compound looks interesting though, basically oral Eloralintide with similar binding affinities. Rodent studies actually look pretty promising, they recently filed for FDA approval (or whatever the first part of human research is in the US).

Small molecule drugs are also much easier to make then complex peptides, so this could be very promising. Once the patent comes out or the compound structure, im sure we will be able to get from research vendors shortly.
 
1774559054848.webp
1774559110392.webp
Dr. Jinzi J. Wu, Founder, Chairman, and CEO of Ascletis, commented: "Ascletis is committed to developing treatments for patients with obesity. Therefore, we are very excited to advance the world's first oral small molecule, eloralintide-like selective amylin receptor agonist into the clinic later this year. We believe ASC39 may provide efficacy and safety similar to Eli Lilly's eloralintide, coupled with the patient convenience and commercial scalability offered by a once-daily oral small molecule drug."


Lillys got some competition haha
 
I'm curious if Eloralintide will end up being available and manufactured for the gray market. My understanding is that in their patents, Lilly attempted to obscure the exact structure of Eloralintide to make it more difficult to copy - learning from their experience with tirz and reta. I don't think China's been all that shy about engaging in corporate espionage and I would assume that the API for clinical trials is already being manufactured in China anyway and the "recipe" could leak from there, too. Hoping this isn't as difficult to make as it sounds like at first blush - seems like this would be a killer additive to tirz or reta.
 
Ai summary of many study's. Man i'm excited for this to be grey.

Cagrilintide and Eloralintide represent two distinct approaches to amylin‑based therapy for obesity. Cagrilintide, as a non‑selective DACRA, has demonstrated clinically meaningful weight loss (11.8% at 68 weeks) and is well into Phase 3 development, both as monotherapy and in the CagriSema combination. Eloralintide, engineered for selective AMY1R agonism, has shown superior weight loss in Phase 2 (up to 20.1% at 48 weeks) with preclinical evidence of better GI tolerability and higher‑quality weight loss (fat mass preservation). The two molecules differ not only in their receptor pharmacology but also in their formulation requirements (Cagrilintide mandates low pH; Eloralintide is stable at neutral pH and room temperature) and their clinical development timelines (CagriSema is filing for approval, while eloralintide + tirzepatide is in early‑stage investigation).


  1. Briere, D. A., Long, A., Bullock, D. M., O’Farrell, L., Bowen, B., Lansu, K., Coskun, T., Moyers, J. S., & Qu, H. (2025). 849‑P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes, 74
  2. Billings, L. K., Hsia, S., Bays, H., Tidemann‑Miller, B., O’Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48‑week phase 2, multicentre, double‑blind, randomised, placebo‑controlled trial. The Lancet, 406(10520), 2631–2643.
  3. Gu, Y.‑M., et al. (2026). Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica, 47(1), 162–172.
  4. Oliveira Carvas, A., et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 118, 105836.
  5. Novo Nordisk. (2025). Novo Nordisk Presents Phase 3 Data for Next‑Generation Amylin Cagrilintide.  
  6. Bhattachar, S., Tham, L. S., Tidemann‑Miller, B., et al. (2026). Eloralintide, a selective, long‑acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 28(4), 2651–2660.


 
Finally. Lets hope it costs about the same as Cagri
A potential issue is that Uther will be the one first out of the gate. Uther's retail prices are expensive for cagri and GLPs. And my understanding is that he no longer does bulk discounts for resellers and GBs.

Uther sells cagri for $150 for a 5-mg kit and $220 for a 10-mg kit. So my hope is the cost to get started with Uther's elora won't be more than $200 or so (not including MOQ and shipping), and it will eventually be available at his US warehouse (as was the case with orfo).

But with elora positioned as "cagri 2.0," up to $300 for a kit of elora seems possible, especially since Uther sells maz for $260 for a 10-mg kit. Also, it will only cost more for Uther or anyone else to have elora tested, with one quote saying $500 with Jano.

Eventually, the mg should be higher for elora's vials since the dosage is 3x as much compared to cagri:
Gemini said:
So hopefully there will be some competition sooner than later. But no word has been given by other vendors like PGB.
 
Last edited:
I mean id pay 300 for an elora kit as long as its at least 10mg a vial, hopefully even more to reach at least 2 target doses per vial. Btw i keep hearing about Uther but have no clue what people are referring to lol.

Thanks!
 
I wonder what the difficulty would be since AFAIK the structure was published with the last trial results?
I thought that he had to have reference samples in order to test. There has to be a supply chain for those reference samples, and it sounds like that may not exist yet.
 
I thought that he had to have reference samples in order to test. There has to be a supply chain for those reference samples, and it sounds like that may not exist yet.
I believe that's true. So it'll probably take some time for him to be able to test it. I'm honestly not sure how long it took for him to be able to test Reta when it came out.
 
I am tempted. But the pricing is the other issue. And if it's not tested and expensive, that's a no.
 

Trending Topics

Latest Posts

Forum Statistics

Threads
17,585
Posts
182,506
Members
59,172
Newest
onicayunq
Back
Top Bottom